Bone markers - Their nature and clinical use

Journal of Medical Biochemistry

Volumn 27, Issue 2, 2008, Pages 117-122

  Theis, Manfred ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Bone markers; Bone metabolism; Osteoporosis

Indexed keywords

BIOLOGICAL MARKER; BONE MARKER; CALCITONIN; PARATHYROID HORMONE; VITAMIN D;

BONE DISEASE; DIAGNOSTIC TEST; HUMAN; LABORATORY TEST; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; REVIEW; RHEUMATOID ARTHRITIS; RICKETS; RISK FACTOR;

EID: 44649155312     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-008-0003-6     Document Type: Review

References (22)

1. Burgeson RE. New collagens, new concepts. Ann Rev Cell Biol 1988; 4: 551-77.
2. Gundberg CM. Biology, Physiology, and Clinical Chemistry of Osteocalcin. J Clin Ligand Assay 1998; 21 (2): 128-38.
3. Alvarez L, Guańabens N, Peris P, Vidal S, Ros I, Monegal A, Bedini JL, Deulofeu R, Pons F, Muńoz-gomez J, Ballesta AM. Usefulness of biochemical markers of bone turnover in assessing response to treatment of Paget's disease. Bone 2001; 29 (5): 447-52.
4. Alvarez L, RicÓs C, Peris P, GuaŃabens N, Monegal A, Pons F, Ballesta AM. Components of biological variation of biochemical parameters in Paget's bone disease. Bone 2000; 26 (6): 571-6.
5. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for Quantifying Type I Collagen Degradation Products in Urine Evaluated. Clin Chem 1994; 40 (11): 2022-5.
6. Fledelius C, Johnsen A, Cloos P, Bonde M, Qvist P. Identification of a β-isomerized aspartyl residue within the c-terminal telopeptide α1 chain of type I collagen. Possible relation to aging of bone. J Bone Miner Res 1996; 11 (Suppl. 1) Abstract No. 113.
7. Orum O, Hansen M, Jensen CH, et al. Procollagen type 1 N-terminal Propeptide (P1NP) as an indicator of type 1 collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 1996; 19 (2): 157-63.
8. Brandt J, Frederiksen JK, Jensen CH, Teisner B. The Nand C-terminal propeptides of human procollagen type 1 (P1NP and P1CP): molecular heterogeneity and assay technology. Pgs. 73-81. In: Bone Markers Biochemical and Clinical Perspectives. Eds. Eastell R, Baumann M, Hoyle NR, Wieczorek L. Dunitz, London 2001.
9. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas F. Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study. J Bone Miner Res 1999; 14: 1614-21.
10. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an Enzyme Immunoassay for a New Marker of Bone Resorption (CrossLaps): Follow-up on Hormone Replacement Therapy and Osteoporosis Risk Assessment. J Clin Endocrinol Metab 1995; 80: 864-8.
11. Ravn P, Clemmesen B, Riis BJ, Christiansen C. The Effect on Bone Mass and Bone Markers of Different Doses of Ibandronate: A New Bisphosphonate for Prevention and Treatment of Postmenopausal Osteoporosis. A 1-year, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study. Bone 1996; 19 (5): 527-33.
12. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Quist P, et al. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopetides of type I collagen. Clin Chem 1998; 44 (11): 2281-9.
13. Christgau S, Rosenquist C, Alexandersen P, Bjarnson NH, Ravn P, Fledelius C, et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products from type I collagen C-telopetides. Clin Chem 1998; 44 (11): 2290-300.
14. Fink E, Cormier C, Steinmetz P, et al. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos Int 2000; 11 (4): 295-303.
15. Garnero P, Stevens RE, Ayres SA, et al. Short-term effects of new synthetic conjugated estrogens on biochemical markers of bone turnover. J Clin Pharmacol 2002; 42 (3): 290-6.
16. Sharp CA, Evans SF, Risteli L, Risteli J, Worsfold M, Davies MWJ. Effects of low- and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older post-menopausal women. Eur J Clin Invest 1996; 26: 763-71.
17. Seibel MJ. Biochemische Marker des Knochenstoffwechsels: Klinische Wertigkeit in der Praxis. Ther Umsch 1998; 55 (11): 676-84.
18. Ganero P, Borel O, Delmas PD. Evaluation of a Fully Automated Serum Assay for C-Terminal Cross-Linking Telopeptide of Type I Collagen in Osteoporosis. Clin Chem 2001; 47 (4): 694-702.
19. Ahmad AM, Hopkins MT, Fraser WD, et al. Parathyroid hormone secretory pattern, circulating activity, and effect upon bone turnover in adult growth hormone deficiency. Bone 2003; 32 (2): 170-9.
20. Blumsohn A, Naylor KE, Timm W, et al. Absence of marked seasonal change in bone turnover: A longitudinal and multicentre cross-sectional study. J Bone Miner Res 2003; 18 (7): 1274-81.
21. Clowes JA, Hannon RA, Yap TS, Hoyle NR, et al. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002; 30 (6): 886-90.
22. Clowes JA, Robinson RT, Heller SR, et al. Acute changes of bone turnover and PTH induced by insulin and glucose: Euglycemic and hypoglycaemic hyperinsulinemic clamp studies. J Clin Endocrinol Metab 2002; 87: 3324-9.